Last reviewed · How we verify

NCT04650191

Surfactant Protein Genetic Variants in COVID-19 Infection

Completed Last updated 15 September 2022
What this trial tests

trial testing Identification of genetic variants in Coronavirus Infection in 300 participants. Completed in 30 June 2022.

Timeline
1 March 2020
Primary endpoint
30 June 2022
30 June 2022

Quick facts

Lead sponsorMilton S. Hershey Medical Center
StatusCompleted
Study typeOBSERVATIONAL
Enrollment300
Start date1 March 2020
Primary completion30 June 2022
Estimated completion30 June 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Milton S. Hershey Medical Center

Who can join

Adults 1 Day to 90, any sex, with Coronavirus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Surfactant protein plays important role in innate immunity against respiratory viral infections. However, investigators have shown that the surfactant protein polymorphisms are associated with severity of various pulmonary diseases such as respiratory syncytial virus (RSV), tuberculosis, pediatric acute lung injury. COVID-19 virus gains entry through the respiratory system and responsible for death due to acute respiratory failure. There is a considerable heterogeneity in presentation of COVID-19 infection from asymptomatic patients to severe infection requiring intensive care and some may die. Considering reports of COVID-19 related deaths/severe disease in the same family, it is possible that genetics play an important role in severity of COVID-19 infection. Investigators propose to study the association of surfactant proteins in COVID-19 patients. Key Objectives: a) Characterize genetic markers within the surfactant protein genes in COVID-19 positive patients, b) To determine if there is a correlation between certain genetic markers and the severity of COVID-19 infection which may be used as a prognostic marker, c) To correlate genetic markers with immune studies.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. The Role of Pulmonary Surfactants in the Treatment of Acute Respiratory Distress Syndrome in COVID-19.
    Wang S, Li Z, Wang X, Zhang S, et al · · 2021 · cited 36× · PMID 34267664 · DOI 10.3389/fphar.2021.698905
  2. Molecular Pathogenesis of Fibrosis, Thrombosis and Surfactant Dysfunction in the Lungs of Severe COVID-19 Patients.
    Krygier A, Szmajda-Krygier D, Świechowski R, Pietrzak J, et al · · 2022 · cited 12× · PMID 36551272 · DOI 10.3390/biom12121845

Verify or expand the search:

Other trials of Identification of genetic variants

Trials testing the same drug.

Other recruiting trials for Coronavirus Infection

Currently open trials in the same condition.

Other Milton S. Hershey Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04650191.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing